This study is about a new medicine called Mim8 for people with haemophilia A, a condition where the blood doesn't clot properly. Some people with haemophilia A have inhibitors, which are substances that keep treatments from working well. Mim8 helps replace a missing part in the blood called Factor VIII (FVIII) to prevent bleeding.

The study could last up to 5.5 years and will end in 2028 or when Mim8 is available in your country. Participants will get Mim8 injections under the skin with a thin needle weekly, biweekly, or monthly, totaling up to 262 injections. Note, there are restrictions on other medicines you can use during this study.

• Study lasts up to 5.5 years; injections up to 262 times.
• Participants must already be in a related study.
• Pregnant women cannot participate.

If you join, the study doctor will guide you on what medicines to avoid and how to handle any bleeds with extra care. It's important to be able to attend all appointments and follow study rules. If you're pregnant or planning to be, you cannot join. Participants must have a legal guardian's consent if needed.